CStone Pharmaceuticals (Stock Code: 2616) announced on January 23, 2026, that its board of directors approved the grant of a total of 15,715,500 share options under the Post-IPO ESOP to 96 grantees. Of this total, 7,000,000 options were granted to a director, and 8,715,500 options were granted to employees (including senior management). The exercise price per share option is HK$5.65, with vesting schedules linked to service periods and performance milestones.

On the same day, the board approved the grant of 8,055,000 restricted share units (RSUs) under the Post-IPO RSU Scheme to 88 grantees. Of these, 4,270,000 were granted to a director, and 3,785,000 were granted to employees (including senior management), also subject to service conditions and performance targets.

Because the share options and RSUs granted to the director exceed 1% of the company’s issued shares in the preceding 12-month period (under Listing Rule 17.03D(1)), both grants to that individual require approval by shareholders at the upcoming annual general meeting (AGM). If approval is not obtained, those particular grants will be revoked. Following the issuance of these share awards, 21,609,669 underlying shares remain available under the company’s Scheme Mandate Limit, and 12,663,640 remain available under the Service Provider Sublimit. The company advises shareholders and potential investors to exercise caution when dealing in its shares pending the AGM decision.